Literature DB >> 17976032

Surface-active liposomes for targeted cancer therapy.

Stavroula Sofou1.   

Abstract

An overview of liposome-based drug-delivery carriers to cancer cells is presented. Properties related to interfacial interactions between liposomes and the biological milieu that determine the fate of liposomes in vivo are discussed. Original approaches to improve specificity for the target and to control the structural responsiveness of liposomes, depending on their immediate environment, with the aim of enhancing the delivered therapeutic doses, are summarized. This review is not exhaustive on research examples of liposomes as carriers for cancer therapy but, rather, aims to describe major directions of designs and strategies over recent years. The current therapeutic trends that exhibit increasingly higher complexity in structures and responses are also discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17976032     DOI: 10.2217/17435889.2.5.711

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  14 in total

Review 1.  Prospects of nano-material in breast cancer management.

Authors:  A K Singh; A Pandey; M Tewari; R Kumar; A Sharma; H P Pandey; H S Shukla
Journal:  Pathol Oncol Res       Date:  2013-02-23       Impact factor: 3.201

2.  Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein.

Authors:  Tao Wang; Gerard G M D'Souza; Deepa Bedi; Olusegun A Fagbohun; L Prasanna Potturi; Brigitte Papahadjopoulos-Sternberg; Valery A Petrenko; Vladimir P Torchilin
Journal:  Nanomedicine (Lond)       Date:  2010-06       Impact factor: 5.307

Review 3.  Engineering nanomedicines for improved melanoma therapy: progress and promises.

Authors:  Di Bei; Jianing Meng; Bi-Botti C Youan
Journal:  Nanomedicine (Lond)       Date:  2010-11       Impact factor: 5.307

4.  Antitumoral activity of L-ascorbic acid-poly- D,L-(lactide-co-glycolide) nanoparticles containing violacein.

Authors:  Dorival Martins; Lucas Frungillo; Maristela C Anazzetti; Patrícia S Melo; Nelson Durán
Journal:  Int J Nanomedicine       Date:  2010-02-02

Review 5.  Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy.

Authors:  Gann Ting; Chih-Hsien Chang; Hsin-Ell Wang; Te-Wei Lee
Journal:  J Biomed Biotechnol       Date:  2010-08-03

6.  Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer.

Authors:  Stavroula Sofou; Richard Enmon; Stig Palm; Barry Kappel; Pat Zanzonico; Michael R McDevitt; David A Scheinberg; George Sgouros
Journal:  J Liposome Res       Date:  2010-01-13       Impact factor: 3.648

7.  Selection of pancreatic cancer cell-binding landscape phages and their use in development of anticancer nanomedicines.

Authors:  Deepa Bedi; James W Gillespie; Valery A Petrenko
Journal:  Protein Eng Des Sel       Date:  2014-06-04       Impact factor: 1.650

8.  Gadolinium-containing phosphatidylserine liposomes for molecular imaging of atherosclerosis.

Authors:  Andrei Maiseyeu; Georgeta Mihai; Thomas Kampfrath; Orlando P Simonetti; Chandan K Sen; Sashwati Roy; Sanjay Rajagopalan; Sampath Parthasarathy
Journal:  J Lipid Res       Date:  2008-11-17       Impact factor: 5.922

9.  Diffuse interface models of locally inextensible vesicles in a viscous fluid.

Authors:  Sebastian Aland; Sabine Egerer; John Lowengrub; Axel Voigt
Journal:  J Comput Phys       Date:  2014-11-15       Impact factor: 3.553

10.  Dendritic nanoconjugates of photosensitizer for targeted photodynamic therapy.

Authors:  Ahu Yuan; Bing Yang; Jinhui Wu; Yiqiao Hu; Xin Ming
Journal:  Acta Biomater       Date:  2015-04-18       Impact factor: 8.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.